Advertisement

“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany

  • André Steven
  • Barbara SeligerEmail author
Meeting Report
  • 29 Downloads

Introduction

This article summarizes the highlights of the presentations during the XIVth “Tumor Immunology Meets Oncology” (TIMO) symposium, which was held May 24–26th 2018 at the Martin-Luther-University Halle-Wittenberg in Halle/Saale, Germany. Basic scientists, translational researchers and clinicians provided talks on topics ranged from immune escape mechanisms, immune modulation, composition of the tumor microenvironment and immune metabolism to the design and optimization of immunotherapies.

This meeting attracted again participants from more than ten nations to discuss the major advances in basic tumor immunology and immunotherapies alone or in combination with other regimes thereby building up a close link between pre-clinical and clinical research.

The complex interactions between the immune system and tumor cells led to the identification of a number of molecules that governs these interactions. One major goal of immunotherapeutic strategies is to overcome the mechanisms...

Keywords

TIMO 2018 Immune escape Tumor microenvironment Immunomonitoring immunotherapy Immune signatures 

Abbreviations

Arg1

Arginase-1

bgn

Biglycan

ccRCC

Clear cell renal cell carcinoma

CPI

Checkpoint inhibitor

EBV

Epstein Barr virus

ECM

Extracellular matrix

EGLN3

Egl nine homolog 3

FCIS

Favorable combined immune signature

FGFR3

Fibroblast growth factor receptor 3

GLUT

Glucose transporter

HNSCC

Head and neck squamous cell cancer

MCT4

Monocarboxylate transporter 4

miRNA

MicroRNA

NAD

Nicotinamide adenine dinucleotide

NB

Neuroblastoma

NGS

Next generation sequencing

OXPHOS

Oxidative phosphorylation

PHD3

Prolyl hydroxylase 3

PMN

Polymorphonuclear

RCC

Renal cell carcinoma

SB

Sleeping beauty

SLC16A3

Solute carrier family 16 member 3

SLN

Sentinel lymph node

SLRP

Small leucine-rich proteoglycan

STING

Stimulator of interferon genes

TAN

Tumor-associated neutrophil

TCGA

The Cancer Genome Atlas

TLS

Tertiary lymphoid structure

TM

Target module

TME

Tumor microenvironment

Treg

Regulatory T cell

UCIS

Unfavorable combined immune signature

Notes

Acknowledgements

We would like to thank all speakers for their participation and Maria Heise for excellent secretarial help.

Author contributions

BS wrote the introduction, the first seven talks, the summary and conclusion. AS made notes during the talks at the conference, summarized the talks and wrote the last 11 talks. Both authors corrected and approved the final version of the manuscript.

Funding

We express our appreciation to the sponsors of the symposium: AstraZeneca GmbH, Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb, CDDF (Cancer Drug Development Forum), Celgene GmbH, Cellex PT, City of Halle, Deutsche Forschungsgemeinschaft (DFG; German Research Foundation), Deutsche Gesellschaft für Immunologie (DGfI; German Society for Immunology), Epiontis GmbH, Essen BioScience Ltd, Fluidigm, GEMoaB GmbH, Immudex USA, Jannsen Cilag GmbH, Lipocalyx GmbH, Miltenyi Biotec GmbH, Roche Pharma AG, Sarstedt, Sciomics GmbH, SERVA GmbH, siTOOLs BioTech GmbH, Society for Immunotherapy of Cancer (SITC), Thermo Fisher Scientific, QIAGEN GmbH.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest. Barbara Seliger is the organizer of the conference.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Medical ImmunologyMartin-Luther-University Halle-WittenbergHalleGermany

Personalised recommendations